# Innoviva, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Innoviva, Inc.). ## Overview Innoviva, Inc. is a U.S.-based diversified biopharmaceutical company built around two main engines: royalty income from respiratory drugs partnered with GSK and a hospital-focused specialty therapeutics business. It also holds strategic healthcare investments, using capital allocation and acquisitions to expand beyond its legacy royalty model. ## Products & services • Royalty interests in RELVAR/BREO ELLIPTA and ANORO ELLIPTA • GIAPREZA for distributive shock in adults • XACDURO for hospital-acquired and ventilator-associated pneumonia • XERAVA for complicated intra-abdominal infections • ZEVTERA for serious bacterial infections • NUZOLVENCE for uncomplicated urogenital gonorrhea - **Royalty portfolio** (66%) — Contractual royalties from GSK sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA. - **Critical care products** (18%) — Hospital-use therapies such as GIAPREZA for shock and XACDURO for severe pneumonia. - **Infectious disease antibiotics** (12%) — Anti-infective products including XERAVA, ZEVTERA and NUZOLVENCE. - **License and other revenue** (1%) — Milestones, supply arrangements and other collaboration-related revenue. - **Strategic healthcare investments** (3%) — Equity stakes, loans and acquired assets that may create future optionality. - Royalty revenue from GSK-partnered respiratory assets - GIAPREZA critical care therapy for septic or distributive shock - XACDURO antibacterial for Acinetobacter pneumonia - XERAVA antibiotic for complicated intra-abdominal infections - ZEVTERA advanced cephalosporin for serious bacterial infections - NUZOLVENCE treatment for uncomplicated urogenital gonorrhea ## Customers Innoviva's royalty customers are ultimately patients treated through GSK's global respiratory franchise, while Innoviva itself receives royalty payments from GSK rather than selling directly to end users. Its operating business sells to hospitals, health systems, distributors and other healthcare purchasing organizations that need acute-care and anti-infective therapies. The company also monetizes value through licensing counterparties and strategic healthcare partners such as Zai Lab and Basilea. - **GSK partnership royalties** (primary) — GSK commercializes RELVAR/BREO and ANORO globally and pays Innoviva royalties on sales. - **Hospitals and health systems** (primary) — Buy GIAPREZA, XACDURO, XERAVA, ZEVTERA and NUZOLVENCE for inpatient care. - **Distributors and GPOs** (secondary) — Purchase and channel Innoviva products into hospital and institutional settings. - **International commercialization partners** (secondary) — Partners such as Zai Lab support ex-U.S. supply, licensing and market access. - **Strategic healthcare investees** (emerging) — Portfolio companies and funds that receive capital, loans or equity support. - GSK as the commercial partner paying royalties on respiratory sales - Hospitals and health systems buying critical care therapies - Distributors and group purchasing organizations in the U.S. channel - Physicians and hospital formularies selecting anti-infective products - Licensing and collaboration partners in ex-U.S. markets ## Geography Innoviva is headquartered in Burlingame, California and operates as a U.S.-based company with global exposure through GSK's respiratory franchise. Its operating products generate U.S. hospital sales and ex-U.S. sales, while royalty revenue is tied to worldwide sales of partnered respiratory products. The company also has licensing and supply activity linked to China and other international markets through collaboration partners. - **United States** (55%) — Estimated from U.S. product sales and U.S.-based royalty pressure. - **Europe** (20%) — Estimated from global GSK respiratory sales and ex-U.S. commercialization. - **Asia-Pacific** (15%) — Estimated from partnered international sales and China-related licensing. - **Rest of world** (10%) — Residual global exposure across royalty and product channels. - Headquartered in Burlingame, California - Royalty exposure is global through GSK's worldwide sales - U.S. hospital sales are a major driver of product revenue - Ex-U.S. product sales include collaboration-driven international markets - China-linked licensing and supply arrangements add partner exposure ## Strategy Innoviva is focused on maximizing value from its GSK royalty stream while scaling its specialty therapeutics platform in critical care and infectious disease. Management is also using capital allocation, acquisitions and strategic investments to broaden the asset base and reduce dependence on any single product or partner. The strategy is designed to convert royalty cash flows into a more diversified biopharmaceutical portfolio with longer-duration growth options. - **Grow the specialty therapeutics platform** (short-term) — Product sales can diversify revenue beyond royalties and improve long-term growth. - **Maximize GSK royalty value** (medium-term) — Royalty cash flow remains the core economic engine and funds portfolio expansion. - **Acquire and invest in healthcare assets** (medium-term) — New assets can create optionality and reduce concentration risk. - Maximize value from the GSK respiratory royalty portfolio - Grow Innoviva Specialty Therapeutics through hospital commercialization - Expand the product set with new launches and licensed assets - Deploy capital into strategic healthcare investments and acquisitions - Use share repurchases and balance-sheet actions to support value creation ## Risks Innoviva remains exposed to concentration in GSK-partnered royalties, so competitive pressure or weaker commercialization of BREO/ANORO can directly reduce cash flow. Its operating business depends on hospital purchasing patterns, product launches and supply execution, while its investment portfolio adds valuation volatility. Like other biopharma companies, it also faces regulatory, patent, manufacturing, cybersecurity and public-health risks that can affect revenue timing and expense levels. - **Dependence on GSK royalty performance** [high] — A large share of value comes from partnered respiratory products sold by GSK. - **Competitive pressure in respiratory markets** [high] — Competing therapies can reduce sales of the underlying products and royalty base. - **Hospital demand and launch execution** [medium] — Product sales depend on formulary access, adoption and procurement timing. - **Fair value volatility in strategic investments** [medium] — Equity and fund investments can swing earnings through unrealized gains/losses. - **Cybersecurity and data integrity** [medium] — Multiple IT platforms and third-party systems increase breach and disruption risk. - Royalty concentration in BREO and ANORO creates partner and product risk - GSK commercialization decisions can materially affect royalty receipts - Hospital product demand can be volatile and channel-dependent - Supply chain or manufacturing issues can disrupt product availability - Strategic investments can create fair-value volatility in earnings - Cybersecurity and data integrity risks can harm operations and reputation ## Accounting Innoviva's revenue recognition is split between point-in-time product sales, royalty income from partner sales and smaller license or milestone streams, so timing can shift meaningfully by quarter. Product revenue is reduced by estimates for chargebacks, discounts, returns and rebates, while royalty revenue depends on partner-reported sales and contractual tiers. The company also records fair-value changes on strategic investments and amortization of capitalized collaboration fees, both of which can materially affect reported earnings. - **Variable consideration on product sales** — Affects GIAPREZA, XACDURO, XERAVA, ZEVTERA and NUZOLVENCE sales - **Royalty accounting and partner reporting** — Impacts BREO/RELVAR and ANORO royalty revenue - **Fair value measurement of investments** — Can create large unrealized gains or losses in earnings - **Amortization of capitalized collaboration fees** — Reduces net royalty revenue each period - Product sales are net of chargebacks, discounts, returns and rebates - Royalty revenue depends on GSK sales reporting and tiered contract terms - License and milestone revenue can create lumpy quarterly results - Fair-value marks on investments can swing non-operating income - Amortization of capitalized collaboration fees reduces net royalty revenue --- *Last updated: 2026-04-28T20:17:33.806874+00:00*